A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer

Urology

Volumn 83, Issue 3, 2014, Pages 592-598

  Vickers, Andrew J ^a   Thompson, Ian M ^b   Klein, Eric ^c   Carroll, Peter R ^d   Scardino, Peter T ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER PREVENTION; CANCER RECURRENCE; CLINICAL DECISION MAKING; CONSERVATIVE TREATMENT; HUMAN; PATIENT COUNSELING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; UROLOGIST;

BIOPSY; DECISION MAKING; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896815720     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.09.075     Document Type: Review

References (40)

1. F.E. Harrell Jr., R.M. Califf, and D.B. Pryor et al. Evaluating the yield of medical tests JAMA 247 1982 2543 2546
2. N.R. Cook, and P.M. Ridker Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures Ann Intern Med 150 2009 795 802
3. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 2008 157 172 discussion 207-12
4. E.W. Steyerberg, M.J. Pencina, and H.F. Lingsma et al. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration Eur J Clin Invest 42 2012 216 228
5. E.W. Steyerberg, A.J. Vickers, and N.R. Cook et al. Assessing the performance of prediction models: a framework for traditional and novel measures Epidemiology 21 2010 128 138
6. S. Loeb, K.A. Roehl, and R.B. Nadler et al. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml J Urol 178 2007 2348 2352 discussion 2352-3
7. D. Ulmert, A.M. Serio, and M.F. O'Brien et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population J Clin Oncol 26 2008 835 841
8. H.B. Carter, L. Ferrucci, and A. Kettermann et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability J Natl Cancer Inst 98 2006 1521 1527
9. M.F. O'Brien, A.M. Cronin, and P.A. Fearn et al. Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively Int J Cancer 128 2011 2373 2381
10. M.F. O'Brien, A.M. Cronin, and P.A. Fearn et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy J Clin Oncol 27 2009 3591 3597
11. A.V. D'Amico, A.A. Renshaw, B. Sussman, and M.H. Chen Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy JAMA 294 2005 440 447
12. C.R. King, S.J. Freedland, and M.K. Terris et al. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database Urology 69 2007 921 926
13. A.J. Vickers, C. Savage, M.F. O'Brien, and H. Lilja Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer J Clin Oncol 27 2009 398 403
14. S. Loeb, and H.B. Carter Point: Impact of prostate-specific antigen velocity on management decisions and recommendations J Natl Compr Canc Netw 11 2013 281 285
15. A.E. Ross, S. Loeb, and P. Landis et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program J Clin Oncol 28 2010 2810 2816
16. K. Fall, H. Garmo, and O. Andren et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer J Natl Cancer Inst 99 2007 526 532
17. A.J. Stephenson, M.W. Kattan, and J.A. Eastham et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era J Clin Oncol 27 2009 4300 4305
18. P.F. Pinsky, G. Andriole, and E.D. Crawford et al. Prostate-specific antigen velocity and prostate cancer gleason grade and stage Cancer 109 2007 1689 1695
19. A.J. Vickers, T. Wolters, and C.J. Savage et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort Eur Urol 56 2009 753 760
20. A.J. Vickers, T. Wolters, and C.J. Savage et al. Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy J Urol 184 2010 907 912
21. T. Wolters, M.J. Roobol, C.H. Bangma, and F.H. Schroder Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European randomized study of screening for prostate cancer (Rotterdam) Eur Urol 55 2009 385 392
22. M. Auprich, H. Augustin, and L. Budaus et al. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy BJU Int 109 2012 1627 1635
23. S.E. Eggener, O. Yossepowitch, and K.A. Roehl et al. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program Urology 71 2008 1016 1019
24. G.L. Andriole, D. Bostwick, and O.W. Brawley et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study J Urol 185 2011 126 131
25. A.J. Vickers, C. Till, and C.M. Tangen et al. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection J Natl Cancer Inst 103 2011 462 469
26. S. Loeb, E.J. Metter, and D. Kan et al. Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer BJU Int 109 2012 508 513 discussion 513-4
27. J. Hilden, and T.A. Gerds A note on the evaluation of novel biomarkers: do not rely on integrated discrimination improvement and net reclassification index Stat Med 2013
28. L.P. Wallner, S.K. Frencher, and J.W. Hsu et al. Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population BJU Int 2013
29. A.J. Vickers, and M. Pencina Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility Eur Urol 2013
30. D.D. Orsted, S.E. Bojesen, P.R. Kamstrup, and B.G. Nordestgaard Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality Eur Urol 2013
31. D. Robinson, G. Sandblom, R. Johansson Scandinavian Prostate Cancer G PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer Urology 72 2008 903 907
32. S.J. Freedland, E.B. Humphreys, and L.A. Mangold et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality J Clin Oncol 25 2007 1765 1771
33. E.S. Antonarakis, Z. Feng, and B.J. Trock et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up BJU Int 109 2012 32 39
34. M.J. Shulman, J.A. Karam, and E.A. Benaim Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer Urology 63 2004 732 736
35. I.M. Thompson, D.P. Ankerst, and C. Chi et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial J Natl Cancer Inst 98 2006 529 534
36. A.J. Stephenson, P.T. Scardino, and J.A. Eastham et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Natl Cancer Inst 98 2006 715 717
37. M.R. Cooperberg, J.F. Hilton, and P.R. Carroll The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy Cancer 117 2011 5039 5046
38. S.E. Eggener, P.T. Scardino, and P.C. Walsh et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy J Urol 185 2011 869 875
39. G. Giovacchini, M. Picchio, and V. Scattoni et al. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy Eur J Nucl Med Mol Imaging 37 2010 1106 1116
40. A.J. Stephenson, P.T. Scardino, and M.W. Kattan et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy J Clin Oncol 25 2007 2035 2041